Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
By: W. Lybaert MD, M. Simoens , Wim Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, PhD, L. De Backer , M. Peeters MD, PhD
Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)